[DNA疫苗技术:设计和交付]。

Q3 Medicine
A A Fando, A A Ilyichev, V R Litvinova, N B Rudometova, L I Karpenko, A P Rudometov
{"title":"[DNA疫苗技术:设计和交付]。","authors":"A A Fando, A A Ilyichev, V R Litvinova, N B Rudometova, L I Karpenko, A P Rudometov","doi":"10.31857/S0026898425010016, EDN: HDKTLK","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic has triggered the development of new directions in vaccine development, among which DNA- and mRNA-based technologies are particularly noteworthy. The platform based on DNA vaccines is developing particularly intensively due to their high stability at ambient temperature and the ability to activate both humoral and cellular immunity. The full cycle of DNA vaccine creation, which includes the construction of plasmid DNA, obtaining a producer strain, fermentation, and purification, takes 2-4 weeks. In addition, the production technology of such vaccines does not require working with dangerous pathogens, which significantly simplifies the process of their production and reduces the overall cost. Over more than 30 years of rapid development, DNA vaccine technology continues to undergo changes. Currently, there is a licensed DNA vaccine for the prevention of COVID-19, and many candidate prophylactic vaccines against viral and bacterial diseases are in clinical trials. This review covers not only the principles of constructing plasmid DNA vaccines, but also new technologies for obtaining DNA constructs, such as minicircular DNA, MIDGE DNA, and Doggybone^(™) DNA. New types of DNA vaccines are interesting because they consist only of the most essential elements for activating the immune response. Such constructs completely lack the sequences necessary for the production of plasmid DNA in bacterial cells, for example, the antibiotic resistance gene. One of the key problems in the development of a DNA vaccine is the method of its delivery to target cells. Currently, various delivery methods are used, both chemical and physical, which are rapidly developing and have already proven themselves to be reliable and effective. The characteristics of some of the most promising methods are also presented in this review.</p>","PeriodicalId":39818,"journal":{"name":"Molekulyarnaya Biologiya","volume":"59 1","pages":"3-21"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[DNA Vaccine Technologies: Design and Delivery].\",\"authors\":\"A A Fando, A A Ilyichev, V R Litvinova, N B Rudometova, L I Karpenko, A P Rudometov\",\"doi\":\"10.31857/S0026898425010016, EDN: HDKTLK\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The COVID-19 pandemic has triggered the development of new directions in vaccine development, among which DNA- and mRNA-based technologies are particularly noteworthy. The platform based on DNA vaccines is developing particularly intensively due to their high stability at ambient temperature and the ability to activate both humoral and cellular immunity. The full cycle of DNA vaccine creation, which includes the construction of plasmid DNA, obtaining a producer strain, fermentation, and purification, takes 2-4 weeks. In addition, the production technology of such vaccines does not require working with dangerous pathogens, which significantly simplifies the process of their production and reduces the overall cost. Over more than 30 years of rapid development, DNA vaccine technology continues to undergo changes. Currently, there is a licensed DNA vaccine for the prevention of COVID-19, and many candidate prophylactic vaccines against viral and bacterial diseases are in clinical trials. This review covers not only the principles of constructing plasmid DNA vaccines, but also new technologies for obtaining DNA constructs, such as minicircular DNA, MIDGE DNA, and Doggybone^(™) DNA. New types of DNA vaccines are interesting because they consist only of the most essential elements for activating the immune response. Such constructs completely lack the sequences necessary for the production of plasmid DNA in bacterial cells, for example, the antibiotic resistance gene. One of the key problems in the development of a DNA vaccine is the method of its delivery to target cells. Currently, various delivery methods are used, both chemical and physical, which are rapidly developing and have already proven themselves to be reliable and effective. The characteristics of some of the most promising methods are also presented in this review.</p>\",\"PeriodicalId\":39818,\"journal\":{\"name\":\"Molekulyarnaya Biologiya\",\"volume\":\"59 1\",\"pages\":\"3-21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molekulyarnaya Biologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31857/S0026898425010016, EDN: HDKTLK\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molekulyarnaya Biologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31857/S0026898425010016, EDN: HDKTLK","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

COVID-19大流行引发了疫苗开发新方向的发展,其中基于DNA和mrna的技术尤其值得关注。基于DNA疫苗的平台由于其在环境温度下的高稳定性以及激活体液和细胞免疫的能力,正在特别密集地发展。DNA疫苗制造的整个周期,包括质粒DNA的构建、获得生产菌株、发酵和纯化,需要2-4周。此外,这种疫苗的生产技术不需要处理危险的病原体,这大大简化了其生产过程并降低了总体成本。经过30多年的快速发展,DNA疫苗技术不断发生变化。目前,预防COVID-19的DNA疫苗已获得许可,许多针对病毒性和细菌性疾病的候选预防性疫苗正在临床试验中。本文不仅综述了构建质粒DNA疫苗的原理,还介绍了获取DNA构建体的新技术,如微环DNA、MIDGE DNA和Doggybone^(™)DNA。新型DNA疫苗很有趣,因为它们只包含激活免疫反应的最基本元素。这种结构完全缺乏在细菌细胞中产生质粒DNA所必需的序列,例如抗生素抗性基因。开发DNA疫苗的关键问题之一是将其递送到靶细胞的方法。目前,使用了各种各样的递送方法,包括化学和物理,这些方法正在迅速发展,并且已经证明自己是可靠和有效的。本文还介绍了一些最有前途的方法的特点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[DNA Vaccine Technologies: Design and Delivery].

The COVID-19 pandemic has triggered the development of new directions in vaccine development, among which DNA- and mRNA-based technologies are particularly noteworthy. The platform based on DNA vaccines is developing particularly intensively due to their high stability at ambient temperature and the ability to activate both humoral and cellular immunity. The full cycle of DNA vaccine creation, which includes the construction of plasmid DNA, obtaining a producer strain, fermentation, and purification, takes 2-4 weeks. In addition, the production technology of such vaccines does not require working with dangerous pathogens, which significantly simplifies the process of their production and reduces the overall cost. Over more than 30 years of rapid development, DNA vaccine technology continues to undergo changes. Currently, there is a licensed DNA vaccine for the prevention of COVID-19, and many candidate prophylactic vaccines against viral and bacterial diseases are in clinical trials. This review covers not only the principles of constructing plasmid DNA vaccines, but also new technologies for obtaining DNA constructs, such as minicircular DNA, MIDGE DNA, and Doggybone^(™) DNA. New types of DNA vaccines are interesting because they consist only of the most essential elements for activating the immune response. Such constructs completely lack the sequences necessary for the production of plasmid DNA in bacterial cells, for example, the antibiotic resistance gene. One of the key problems in the development of a DNA vaccine is the method of its delivery to target cells. Currently, various delivery methods are used, both chemical and physical, which are rapidly developing and have already proven themselves to be reliable and effective. The characteristics of some of the most promising methods are also presented in this review.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Molekulyarnaya Biologiya
Molekulyarnaya Biologiya Medicine-Medicine (all)
CiteScore
0.70
自引率
0.00%
发文量
131
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信